Recon Strategy
Contact

Insights

Fifteen+ years of
Healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

Sector
All
NEJM opinion

Outcomes Based Arrangements in Biopharma

  • Biopharma , 
  • Payers , 
  • Institutional
Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.

Read more

Kidney transplantation, improved but still a significant missed opportunity

  • Payers , 
  • Providers , 
  • Institutional
In order to make a more immediate and significant impact on dialysis and kidney waitlist, OPOs need to ensure that significantly more potential donors are identified, and all necessary steps are taken to ensure that a potential donor becomes an actual organ donor.

Read more

Incentivizing even small progress in Alzheimer’s therapy should be a priority

  • Biopharma , 
  • Institutional
Working paper: Over the coming decades, Alzheimer’s disease threatens …

Read more

Ochsner signs LOI to enter northern Louisiana and secure a medical school affiliation

  • Providers , 
  • Institutional
(For Louisiana market context, please take a look at previous notes on…

Read more